210 related articles for article (PubMed ID: 18027153)
1. Alpha-v integrins as therapeutic targets in oncology.
Nemeth JA; Nakada MT; Trikha M; Lang Z; Gordon MS; Jayson GC; Corringham R; Prabhakar U; Davis HM; Beckman RA
Cancer Invest; 2007 Oct; 25(7):632-46. PubMed ID: 18027153
[TBL] [Abstract][Full Text] [Related]
2. Role of integrin receptors for fibronectin, collagen and laminin in the regulation of ovarian carcinoma functions in response to a matrix microenvironment.
Ahmed N; Riley C; Rice G; Quinn M
Clin Exp Metastasis; 2005; 22(5):391-402. PubMed ID: 16283482
[TBL] [Abstract][Full Text] [Related]
3. Chemically programmed antibodies targeting multiple alpha(v) integrins and their effects on tumor-related functions in vitro.
Goswami RK; Bajjuri KM; Forsyth JS; Das S; Hassenpflug W; Huang ZZ; Lerner RA; Felding-Habermann B; Sinha SC
Bioconjug Chem; 2011 Aug; 22(8):1535-44. PubMed ID: 21774545
[TBL] [Abstract][Full Text] [Related]
4. Integrin-Targeted Peptide- and Peptidomimetic-Drug Conjugates for the Treatment of Tumors.
Arosio D; Manzoni L; Corno C; Perego P
Recent Pat Anticancer Drug Discov; 2017; 12(2):148-168. PubMed ID: 28164756
[TBL] [Abstract][Full Text] [Related]
5. Endothelial alpha5 and alphav integrins cooperate in remodeling of the vasculature during development.
van der Flier A; Badu-Nkansah K; Whittaker CA; Crowley D; Bronson RT; Lacy-Hulbert A; Hynes RO
Development; 2010 Jul; 137(14):2439-49. PubMed ID: 20570943
[TBL] [Abstract][Full Text] [Related]
6. Functional overlap and cooperativity among alphav and beta1 integrin subfamilies during skin angiogenesis.
Perruzzi CA; de Fougerolles AR; Koteliansky VE; Whelan MC; Westlin WF; Senger DR
J Invest Dermatol; 2003 Jun; 120(6):1100-9. PubMed ID: 12787141
[TBL] [Abstract][Full Text] [Related]
7. Anti-angiogenic cancer therapy based on integrin alphavbeta3 antagonism.
Cai W; Chen X
Anticancer Agents Med Chem; 2006 Sep; 6(5):407-28. PubMed ID: 17017851
[TBL] [Abstract][Full Text] [Related]
8. Targeting of alpha-v integrins reduces malignancy of bladder carcinoma.
van der Horst G; Bos L; van der Mark M; Cheung H; Heckmann B; Clément-Lacroix P; Lorenzon G; Pelger RC; Bevers RF; van der Pluijm G
PLoS One; 2014; 9(9):e108464. PubMed ID: 25247809
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Cancer Cell Adhesion, Migration and Proliferation by a Bispecific Antibody that Targets two Distinct Epitopes on αv Integrins.
Gallo E; Kelil A; Haughey M; Cazares-Olivera M; Yates BP; Zhang M; Wang NY; Blazer L; Carderelli L; Adams JJ; Kossiakoff AA; Wells JA; Xie W; Sidhu SS
J Mol Biol; 2021 Jul; 433(15):167090. PubMed ID: 34090922
[TBL] [Abstract][Full Text] [Related]
10. Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: which side to target?
Rüegg C; Dormond O; Foletti A
Endothelium; 2002; 9(3):151-60. PubMed ID: 12380640
[TBL] [Abstract][Full Text] [Related]
11. Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
Jia J; Starodub A; Cushman I; Liu Y; Marshall DJ; Hurwitz HI; Nixon AB
Anticancer Drugs; 2013 Mar; 24(3):237-50. PubMed ID: 23275294
[TBL] [Abstract][Full Text] [Related]
12. The biology of integrins.
Stupack DG
Oncology (Williston Park); 2007 Aug; 21(9 Suppl 3):6-12. PubMed ID: 17927025
[TBL] [Abstract][Full Text] [Related]
13. Small molecule alpha(v) integrin antagonists: novel anticancer agents.
Kerr JS; Slee AM; Mousa SA
Expert Opin Investig Drugs; 2000 Jun; 9(6):1271-9. PubMed ID: 11060742
[TBL] [Abstract][Full Text] [Related]
14. Endothelial cell integrins and COX-2: mediators and therapeutic targets of tumor angiogenesis.
Rüegg C; Dormond O; Mariotti A
Biochim Biophys Acta; 2004 Mar; 1654(1):51-67. PubMed ID: 14984767
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of integrin alphav promotes human osteosarcoma cell populated collagen lattice contraction and cell migration.
Levinson H; Hopper JE; Ehrlich HP
J Cell Physiol; 2002 Nov; 193(2):219-24. PubMed ID: 12384999
[TBL] [Abstract][Full Text] [Related]
16. CNTO 95, a fully human monoclonal antibody that inhibits alphav integrins, has antitumor and antiangiogenic activity in vivo.
Trikha M; Zhou Z; Nemeth JA; Chen Q; Sharp C; Emmell E; Giles-Komar J; Nakada MT
Int J Cancer; 2004 Jun; 110(3):326-35. PubMed ID: 15095296
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic combination tumor therapy blocking alpha(v)-integrins and VEGF-receptor-2 increases therapeutic effects in vivo.
Strieth S; Eichhorn ME; Sutter A; Jonczyk A; Berghaus A; Dellian M
Int J Cancer; 2006 Jul; 119(2):423-31. PubMed ID: 16477628
[TBL] [Abstract][Full Text] [Related]
18. Genetic depletion and pharmacological targeting of αv integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models.
Li Y; Drabsch Y; Pujuguet P; Ren J; van Laar T; Zhang L; van Dam H; Clément-Lacroix P; Ten Dijke P
Breast Cancer Res; 2015 Feb; 17(1):28. PubMed ID: 25849225
[TBL] [Abstract][Full Text] [Related]
19. Integrin alpha v beta 3 antagonists for anti-angiogenic cancer treatment.
Hsu AR; Veeravagu A; Cai W; Hou LC; Tse V; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jun; 2(2):143-58. PubMed ID: 18221059
[TBL] [Abstract][Full Text] [Related]
20. Role of integrins in cancer: survey of expression patterns.
Mizejewski GJ
Proc Soc Exp Biol Med; 1999 Nov; 222(2):124-38. PubMed ID: 10564536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
